866-997-4948(US-Canada Toll Free)

Ewing Sarcoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 81 Pages

Ewing Sarcoma - Pipeline Review, H1 2014

Summary

Global Markets Directs, Ewing Sarcoma - Pipeline Review, H1 2014, provides an overview of the Ewing Sarcomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ewing Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ewing Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ewing Sarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Ewing Sarcoma - Overview 8
Pipeline Products for Ewing Sarcoma - Comparative Analysis 9
Ewing Sarcoma - Therapeutics under Development by Companies 10
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 12
Ewing Sarcoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Ewing Sarcoma - Products under Development by Companies 15
Ewing Sarcoma - Products under Investigation by Universities/Institutes 16
Ewing Sarcoma - Companies Involved in Therapeutics Development 17
Shionogi & Co., Ltd. 17
Amgen Inc. 18
AstraZeneca PLC 19
Daiichi Sankyo Company, Limited 20
Sigma-Tau S.p.A. 21
Oncolytics Biotech Inc. 22
Merrimack Pharmaceuticals, Inc. 23
Pharma Mar, S.A. 24
EntreChem, S.L. 25
Ewing Sarcoma - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
olaparib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ganitumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pelareorep - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PM-00104 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
exatecan mesylate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
niraparib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
irinotecan sucrosofate liposomal - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Peptide Cocktail Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SST-0001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LSD-1 Inhibitor - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dactinomycin reformulation - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
EC-8105 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CytoPep - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Ewing Sarcoma - Recent Pipeline Updates 63
Ewing Sarcoma - Dormant Projects 75
Ewing Sarcoma - Discontinued Products 76
Ewing Sarcoma - Product Development Milestones 77
Featured News & Press Releases 77
Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma 77
Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma 77
Mar 31, 2012: Researchers State Combination Of Two Targeted Therapies Act Against Ewing's Sarcoma Tumors 78
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Table

List of Tables
Number of Products under Development for Ewing Sarcoma, H1 2014 8
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H1 2014 17
Ewing Sarcoma - Pipeline by Amgen Inc., H1 2014 18
Ewing Sarcoma - Pipeline by AstraZeneca PLC, H1 2014 19
Ewing Sarcoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 20
Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H1 2014 21
Ewing Sarcoma - Pipeline by Oncolytics Biotech Inc., H1 2014 22
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 23
Ewing Sarcoma - Pipeline by Pharma Mar, S.A., H1 2014 24
Ewing Sarcoma - Pipeline by EntreChem, S.L., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Assessment by Combination Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H1 2014 63
Ewing Sarcoma - Dormant Projects, H1 2014 75
Ewing Sarcoma - Discontinued Products, H1 2014 76

List of Chart

List of Figures
Number of Products under Development for Ewing Sarcoma, H1 2014 8
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *